Letters to the EditorNegligible excretion of 5-aminosalicylic acid in breast milk
References (3)
Cited by (40)
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
2016, GastroenterologyCitation Excerpt :In addition, a meta-analysis201 and more recent case-control studies202,203 have suggested that breast-feeding may have a protective effect against the development of early-onset IBD in the offspring. Data suggest that the amount of 5-ASA preparations and sulfasalazine metabolites excreted in breast milk is low, and they are considered safe to use while breast-feeding.15,204–207 Corticosteroids are found in low concentrations in breast milk,208,209 and although several guidelines suggest that women be advised to avoid breast-feeding within 4 hours of drug administration,15,116 this consensus group did not.
FERTILITY AND PREGNANCY IN PATIENTS WITH INFLAMATORY BOWEL DISEASE
2015, Revista Medica Clinica Las CondesGastrointestinal drugs
2015, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third EditionUpdate on pregnancy and breastfeeding in the era of biologics
2013, Digestive and Liver DiseaseCitation Excerpt :Folic acid supplementation has been shown to reduce the risk of cleft palate and cardiovascular teratogenicity [42]. The amount of aminosalicylate metabolites excreted in breast milk is negligible, and is considered low risk for nursing [43]. In men, sulfasalazine induces oligospermia and abnormal sperm morphology and function, which can lead to impaired fertility.
Gastrointestinal Drugs
2007, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Second EditionGastrointestinal drugs
2007, Drugs During Pregnancy and Lactation